描述:
CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and
presumably Secreted), is an 8 kDa βchemokine that plays a primary role in the inflammatory
immune response by means of its ability to attract and activate leukocytes. Human and mouse
RANTES exhibit crossspecies activity on human and mouse cells. Mature human CCL5 shares
75% 84% aa sequence identity with canine, cotton rat, feline, mouse, and rat CCL5. CCL5 is
secreted by many cell types at inflammatory sites, and it exerts a wide range of activities
through the receptors CCR1, CCR3, CCR4, and CCR5. Inflammatory responses can be impaired
by the sequestration of CCL5 by the cytomegalovirus protein US28. In humans, CCR5 binding to
CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV1. The two
Nterminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that
functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV1 infection of
monocytes. Oligomerization of CCL5 on glycosaminoglycans is required for CCR1mediated
leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/
PF4. The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte
adhesion to damaged vasculature, but CCL5 oligomerization is not required for the
extravasation of adherent leukocytes. CCL5 is upregulated in breast cancer and promotes
tumor progression through the attraction of proinflammatory macrophages in addition to
its actions on tumor cells, stromal cells, and the vasculature. The Met RANTES preparation
from R&D Systems has been shown to be a partial agonist in monocyte chemotactic assays,
exhibiting an ED50 10-20 fold higher than that of recombinant RANTES.
原厂资料:
CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and
presumably Secreted), is an 8 kDa βchemokine that plays a primary role in the inflammatory
immune response by means of its ability to attract and activate leukocytes. Human and mouse
RANTES exhibit crossspecies activity on human and mouse cells. Mature human CCL5 shares
75% 84% aa sequence identity with canine, cotton rat, feline, mouse, and rat CCL5. CCL5 is
secreted by many cell types at inflammatory sites, and it exerts a wide range of activities
through the receptors CCR1, CCR3, CCR4, and CCR5. Inflammatory responses can be impaired
by the sequestration of CCL5 by the cytomegalovirus protein US28. In humans, CCR5 binding to
CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV1. The two
Nterminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that
functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV1 infection of
monocytes. Oligomerization of CCL5 on glycosaminoglycans is required for CCR1mediated
leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/
PF4. The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte
adhesion to damaged vasculature, but CCL5 oligomerization is not required for the
extravasation of adherent leukocytes. CCL5 is upregulated in breast cancer and promotes
tumor progression through the attraction of proinflammatory macrophages in addition to
its actions on tumor cells, stromal cells, and the vasculature. The Met RANTES preparation
from R&D Systems has been shown to be a partial agonist in monocyte chemotactic assays,
exhibiting an ED50 10-20 fold higher than that of recombinant RANTES.